Visit Zepbound™ (tirzepatide) is approved by Health Canada specifically for the chronic weight management — an indication distinct from that of Mounjaro, which contains the same active ingredient but is intended for the treatment of type 2 diabetes. Administered using the KwikPen® injection pen, Zepbound also stands out for its dual mechanism of action.
On this page
- What is Zepbound (tirzepatide)?
- Zepbound and Mounjaro: Same Molecule, Different Indications
- The dual GIP + GLP-1 mechanism
- Who is eligible to apply for Zepbound?
- Protocol for Administration and Medical Monitoring
- Side Effects and Precautions
- Access to Zepbound in Quebec
- Myths and misconceptions
- Frequently asked questions
What is Zepbound (tirzepatide)?
Visit tirzepatide is a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, a combination that distinguishes it from GLP-1 agonists alone, such as semaglutide or liraglutide. Zepbound is the tirzepatide formulation approved by Health Canada specifically for chronic weight management in adults, administered once weekly by subcutaneous injection using the KwikPen® injection pen.
To remember
- Zepbound contains tirzepatide, a dual GIP and GLP-1 agonist
- Weekly subcutaneous injection using the KwikPen® pen
- Approved by Health Canada specifically for weight management, not for diabetes
- Mounjaro's dosage and distinct titration steps
- Always prescribed as a supplement to a diet and exercise plan
- Requires a prior medical evaluation and regular follow-up
Zepbound and Mounjaro: Same Molecule, Different Indications
Both Zepbound and Mounjaro contain tirzepatide, but Health Canada has approved them for different indications:
| Product | Approved Indication |
|---|---|
| Zepbound | Chronic Weight Management |
| Mounjaro | Treatment of Type 2 Diabetes |
As with the Wegovy/Ozempic combination, the dosage levels differ between the two products depending on their respective indications. The choice is based strictly on medical evaluation, depending on the patient’s diagnosis and treatment goals.
The dual GIP + GLP-1 mechanism
- Combined action on two distinct hormone receptors involved in the regulation of appetite and metabolism
- Slower gastric emptying, prolonging the feeling of fullness
- The effect may be more pronounced than that of GLP-1 agonists alone; this should be evaluated on a case-by-case basis with the treating physician
Who is eligible to apply for Zepbound?
Eligibility for Zepbound is based on specific clinical criteria, as assessed by a doctor:
| Criteria | General Threshold |
|---|---|
| Body Mass Index (BMI) | ≥ 30 kg/m² |
| BMI with associated comorbidities | ≥ 27 kg/m² |
| Preliminary Medical Evaluation | Required |
Protocol for Administration and Medical Monitoring
The KwikPen® Pen
Zepbound is administered using a prefilled KwikPen® injection pen, designed to simplify weekly self-injection. Patients are instructed on the injection technique during their initial follow-up visit.
Clinical follow-up required
- Comprehensive initial evaluation (medical history, comorbidities, contraindications)
- Gradual adjustment of the dose based on tolerance
- Periodic Monitoring of Treatment Response
- Reassessment of the appropriateness of continuing treatment in the medium term
Side Effects and Precautions
The most commonly reported side effects are gastrointestinal (nausea, transient gastrointestinal symptoms), especially at the start of treatment or during dose adjustments. Certain contraindications exist, including specific personal or family history. Only a healthcare professional can determine whether this treatment is appropriate based on a patient’s complete medical history.
Access to Zepbound in Quebec
Access to Zepbound requires a medical consultation to assess eligibility, medical history, and health goals. Our service locations in Quebec offer both in-person and telemedicine consultations for this type of evaluation.
A comprehensive medical evaluation is the first step in determining whether Zepbound is an appropriate option for you. Make an appointment at one of our service locations in Quebec, or choose a online consultation. Companies interested in a wellness program for their employees can review our offerings for companies.
Myths and misconceptions
«Zepbound and Mounjaro are exactly the same.»
Nuanced. Same molecule, but with different approved indications and dosage levels—Zepbound is intended for weight management, while Mounjaro is intended for type 2 diabetes.
«The dual mechanism ensures better results for everyone»
Nuanced. The response to treatment varies from person to person—a dual mechanism does not guarantee superior results for every patient.
«Anyone can get Zepbound»
False. A medical evaluation and a prescription are required, along with monitoring of clinical eligibility.
«The KwikPen® pen is hard to use.»
False. The KwikPen® is designed for self-injection, and patients are taught the technique during their initial follow-up visit with the healthcare team.
«The treatment is permanent.»
Nuanced. The duration of treatment is determined in consultation with the treating physician based on the clinical response and the established goals.
Frequently asked questions
Is Zepbound covered by RAMQ?
Coverage varies depending on the insurance plan and eligibility criteria. It is recommended that you check your specific coverage with your insurer or the RAMQ.
Can Mounjaro be used instead of Zepbound?
No, not without a medical evaluation. Even if the active ingredient is the same, the dosage and indication differ—only a doctor can determine the appropriate medication and dosage.
How long before I see results?
The timeframes vary from person to person depending on several individual factors. Regular medical follow-up allows for an assessment of progress and adjustments to the treatment plan.
Is the Zepbound suitable for everyone?
No. Eligibility depends on specific clinical criteria (BMI, comorbidities, medical history) that are evaluated on a case-by-case basis during the medical consultation.
What is the difference between Zepbound and Wegovy?
Both are approved for weight management, but they contain different active ingredients: Zepbound acts on two receptors (GIP and GLP-1), while Wegovy acts on only one (GLP-1). The choice depends on an individualized medical evaluation.
Sources
- Health Canada — Pharmaceutical Products Database
- National Institute for Excellence in Health and Social Services (INESSS)
- Quebec Ministry of Health and Social Services (MSSS)
- Quebec College of Physicians (CMQ) — Guidelines on Weight Management
- Quebec Health Insurance Board (RAMQ)
Recommended Reading
- Mounjaro in Quebec: The Complete Guide
- Wegovy in Quebec: semaglutide for weight management
- Saxenda in Quebec: Liraglutide for Weight Management
- World Obesity Day: Medical Care in Quebec
- GLP-1 Agonists: A Comparison of Options Approved in Quebec
This information is provided for educational purposes only and is not a substitute for the advice of a healthcare professional. Consult a doctor if you have any questions about your health.
Omicron Clinic
Need to consult a doctor?
In-person or via telemedicine, anywhere in Quebec.
We accept insurance. Telemedicine consultations available 7 days a week. No family doctor required.
